Topic: If MEK/BRAF Positive, this FDA priority review may be of interest
Trametinib (GSK 1120212) a MEK inhibitor used in the clinical trial MEK/pazopanib that one of our member is on now.
Priority review means faster approval by FDA if results are encouraging .
Most of the time ,if this regimen gets fast tract approval, it can be used"off label" for other kinds of cancer like CCA.
Both drugs have been approval by the FDA individually earlier but not the combined regimen.